EMA Application withdrawn: Febseltiq (Infigratinib monophosphate) — Helsinn Birex Pharmaceuticals Ltd

View source ↗

Summary

Application withdrawn for Febseltiq (Infigratinib monophosphate) by Helsinn Birex Pharmaceuticals Ltd in relation to cholangiocarcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cholangiocarcinoma

Drugs mentioned

• Febseltiq (Infigratinib monophosphate)

Snippet

Status: Application withdrawn. Therapeutic area: Cholangiocarcinoma. MAH: Helsinn Birex Pharmaceuticals Ltd. Orphan medicine